Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics Inc (NQ: ALLO )

2.785 +0.025 (+0.91%)
Streaming Delayed Price Updated: 12:05 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Recap: Allogene Therapeutics Q4 Earnings
Via Benzinga
Allogene Therapeutics Earnings Preview
Via Benzinga
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Via Benzinga
Topics ETFs
3 Meme Stocks to Sell and Replace With Meme Coins
For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs. 
Via InvestorPlace
Allogene Therapeutics Announces Q2 Investor Conference Participation
From Allogene Therapeutics, Inc.
Via GlobeNewswire
ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023
ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
Exposures US Equities
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says Analyst
Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal... 
Via Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc. 
Via Benzinga
Allogene Layoffs 2024: What to Know About the Latest ALLO Job Cuts
Today, investors in Allogene and ALLO stock aren't cheering a cash burn reduction strategy, with the stock sinking over 15% on the news. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! 
Via InvestorPlace
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
From Allogene Therapeutics, Inc.; Foresight Diagnostics
Via GlobeNewswire
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.